The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Design and Production of Bispecific Antibodies
Open accessAbstract
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Recombinant protein expression in Escherichia coli: advances and challenges
Rosano, G. L., & Ceccarelli, E. A. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00172 · Cited by 2,556
The packing of α-helices: simple coiled-coils
Crick, F. H. C. (1953) · Acta Crystallographica · doi:10.1107/s0365110x53001964 · Cited by 1,578
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
The production of recombinant pharmaceutical proteins in plants
Ma, J. K.-C., Drake, P. M. W., & Christou, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1177 · Cited by 960
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“Numerous studies have demonstrated that the amino acid sequence of the CH2 and CH3 domain and the Fc conserved glycan profile both impact the antibody ADCC and CDC activities [11].”
Background‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760
Cell-free protein synthesis: Applications come of age
Carlson, E. D., Gan, R., Hodgman, C. E., & Jewett, M. C. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.09.016 · Cited by 706
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
A comparison of strategies to stabilize immunoglobulin Fv-fragments
Glockshuber, R., Malia, M., Pfitzinger, I., & Plueckthun, A. (1990) · Biochemistry · doi:10.1021/bi00458a002 · Cited by 473
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process
Singh, A., Upadhyay, V., Upadhyay, A. K., Singh, S. M., & Panda, A. K. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0222-8 · Cited by 444
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Blinatumomab: A historical perspective
Nagorsen, D., Kufer, P., Baeuerle, P. A., & Bargou, R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.013 · Cited by 355
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Sequence Statistics Reliably Predict Stabilizing Mutations in a Protein Domain
Steipe, B., Schiller, B., Plückthun, A., & Steinbacher, S. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1434 · Cited by 338
Argos, P. (1990) · Journal of Molecular Biology · doi:10.1016/0022-2836(90)90085-z · Cited by 334
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320 · cited 2×
“Therefore, this antibody is administere as a 4-week continuous intravenous (IV) infusion t maintain s fficient therapeutic serum concentration [37], which i creases costs by havi g to produce more clinical-grade antibodies [39].”
BackgroundAn improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
Whitlow, M., Bell, B. A., Feng, S.-L., Filpula, D., Hardman, K. D., Hubert, S. L., Rollence, M. L., Wood, J. F., Schott, M. E., Milenic, D. E., et al. (1993) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/6.8.989 · Cited by 318
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2007) · Cancer · doi:10.1002/cncr.22402 · Cited by 281
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Aggregation-resistant domain antibodies selected on phage by heat denaturation
Jespers, L., Schon, O., Famm, K., & Winter, G. (2004) · Nature Biotechnology · doi:10.1038/nbt1000 · Cited by 266
Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
Verma, R., Boleti, E., & George, A. J. T. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00077-5 · Cited by 265
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306449 · Cited by 260
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Antibody scFv fragments without disulfide bonds, made by molecular evolution
Proba, K., Wörn, A., Honegger, A., & Plückthun, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1457 · Cited by 239
Tailoring in vitro evolution for protein affinity or stability
Jermutus, L., Honegger, A., Schwesinger, F., Hanes, J., & Plückthun, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.75 · Cited by 233
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 228
Bispecific antibodies for cancer therapy: A review
Krishnamurthy, A., & Jimeno, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.002 · Cited by 223
Expression of an antibody fragment at high levels in the bacterial cytoplasm
Martineau, P., Jones, P., & Winter, G. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1840 · Cited by 220
[3] Protein engineering of single-chain Fv analogs and fusion proteins
Huston, J. S., Mudgett-Hunter, M., Tai, M.-S., McCartney, J., Warren, F., Haber, E., & Oppermann, H. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)03005-2 · Cited by 215
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 1×
“The content of chimeric mouse/rat bsAb was significantly enriched due to preferential species-restricted heavy/light-chain pairing in contrast to the random pairing in conventional mouse/mouse or rat/rat quadromas [152,153].”
BackgroundSelection for improved protein stability by phage display 1 1Edited by J. A. Wells
Jung, S., Honegger, A., & Plückthun, A. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3196 · Cited by 203
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., & Schirrmann, T. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-52 · Cited by 200
Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R. A., Zangemeister‐Wittke, U., & Plückthun, A. (1999) · PubMed · Cited by 200
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C. D., Tsai, L., Gajjar, M. R., Sun, M., Seaman, M. S., Padte, N. N., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.024 · Cited by 199
Spiess, C., Merchant, M., Huang, A., Zheng, Z., Yang, N.-Y., Peng, J., Ellerman, D., Shatz, W., Reilly, D., Yansura, D. G., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2621 · Cited by 197
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
Monoclonal antibodies in cancer immunotherapy
Kimiz-Gebologlu, I., Gulce-Iz, S., & Biray-Avci, C. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4427-x · Cited by 194
Prokaryotic expression of antibodies
Arbabi-Ghahroudi, M., Tanha, J., & MacKenzie, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-6193-1 · Cited by 191
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Klein, C., Schaefer, W., & Regula, J. T. (2016) · mAbs · doi:10.1080/19420862.2016.1197457 · Cited by 185
Zhou, X., Hu, W., & Qin, X. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0089 · Cited by 178
Bispecific human IgG by design
Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167
Reusch, U., Burkhardt, C., Fucek, I., Le Gall, F., Le Gall, M., Hoffmann, K., Knackmuss, S. H., Kiprijanov, S., Little, M., & Zhukovsky, E. A. (2014) · mAbs · doi:10.4161/mabs.28591 · Cited by 161
[17] Bispecific monoclonal antibodies from hybrid hybridomas
Suresh, M. R., Cuello, A. C., & Milstein, C. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)21019-8 · Cited by 160
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
Joosten, V., Lokman, C., van den Hondel, C. A. M. J. J., & Punt, P. J. (2003) · Microbial Cell Factories · doi:10.1186/1475-2859-2-1 · Cited by 159
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schäfer, W. M., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2018) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 158
Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting
Jung, S. C., & Plückthun, A. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.8.959 · Cited by 157
Strohl, W. R., & Naso, M. F. (2019) · Antibodies · doi:10.3390/antib8030041 · Cited by 154
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Labrijn, A. F., Meesters, J. I., Priem, P., de Jong, R. N., van den Bremer, E. T. J., van Kampen, M. D., Gerritsen, A. F., Schuurman, J., & Parren, P. W. H. I. (2014) · Nature Protocols · doi:10.1038/nprot.2014.169 · Cited by 150
Pabla, B., Bissonnette, M., & Konda, V. J. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i5.133 · Cited by 148
Pantoliano, M. W., Bird, R. E., Johnson, S., Asel, E. D., Dodd, S. W., Wood, J. F., & Hardman, K. D. (1991) · Biochemistry · doi:10.1021/bi00106a007 · Cited by 145
Fine architecture of bacterial inclusion bodies
Carrió, M., Cubarsí, R., & Villaverde, A. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01357-0 · Cited by 144
Reiter, Y., Brinkmann, U., Lee, B., & Pastan, I. H. (1996) · Nature Biotechnology · doi:10.1038/nbt1096-1239 · Cited by 140
Wörn, A., der Maur, A. A., Escher, D., Honegger, A., Barberis, A., & Plückthun, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2795 · Cited by 140
Stability engineering of scFvs for the development of bispecific and multivalent antibodies
Miller, B., Demarest, S. J., Lugovskoy, A. A., Huang, F., Wu, X., Snyder, W. B., Croner, L. J., Wang, N. C., Amatucci, A., Michaelson, J. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq028 · Cited by 139
Reusch, U., Duell, J., Ellwanger, K., Herbrecht, C., Knackmuss, S. H. J., Fucek, I., Eser, M., McAleese, F., Molkenthin, V., Gall, F. L., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1029216 · Cited by 134
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
Liu, H., Saxena, A., Sidhu, S. S., & Wu, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 131
Tustian, A. D., Endicott, C. E., Adams, B., Mattila, J., & Bak, H. (2016) · mAbs · doi:10.1080/19420862.2016.1160192 · Cited by 129
Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3
Desplancq, D., King, D. J., Lawson, A. D. G., & Mountain, A. (1994) · Protein Engineering Design and Selection · doi:10.1093/protein/7.8.1027 · Cited by 127
Wörn, A., & Plückthun, A. (1998) · Biochemistry · doi:10.1021/bi980712q · Cited by 126
Portell, C. A., Wenzell, & Advani, A. S. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s42689 · Cited by 125
The development of bispecific antibodies and their applications in tumor immune escape
Zhang, X., Yang, Y., Fan, D., & Xiong, D. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0072-7 · Cited by 122
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 121
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 120
Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.-F., Moine, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms7113 · Cited by 120
Goel, A., Colcher, D. M., Baranowska‐Kortylewicz, J., Augustine, S. C., Booth, B. J. M., Pavlínková, G., & Batra, S. K. (2000) · PubMed · Cited by 117
Ewert, S., Honegger, A., & Plückthun, A. (2003) · Biochemistry · doi:10.1021/bi026448p · Cited by 112
Miller, K. D., Weaver-Feldhaus, J., Gray, S. A., Siegel, R. W., & Feldhaus, M. J. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.04.015 · Cited by 111
Sloan, D. D., Lam, C. K., Irrinki, A., Liu, L., Tsai, A., Pace, C. S., Kaur, J., Murry, J. P., Balakrishnan, M., Moore, P. A., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005233 · Cited by 110
Pavlínková, G., Beresford, G., Booth, B. J. M., Batra, S. K., & Colcher, D. M. (1999) · PubMed · Cited by 107
Nardis, C. D., Hendriks, L. J. A., Poirier, E., Arvinte, T., Gros, P., Bakker, A. B. H., & de Kruif, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793497 · Cited by 105
Root, A. R., Cao, W., Li, B., LaPan, P., Meade, C., Sanford, J. D., Jin, M., O’Sullivan, C., Cummins, E., Lambert, M. A., et al. (2016) · Antibodies · doi:10.3390/antib5010006 · Cited by 103
Jain, S., Aresu, L., Comazzi, S., Shi, J., Worrall, E. G., Clayton, J., Humphries, W., Hemmington, S., Davis, P. J., Murray, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148366 · Cited by 100
Dolezal, O., Pearce, L. A., Lawrence, L. J., McCoy, A. J., Hudson, P. J., & Kortt, A. A. (2000) · Protein Engineering Design and Selection · doi:10.1093/protein/13.8.565 · Cited by 99
Gruber, M., Schodin, B. A., Wilson, E. R., & Kranz, D. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.11.5368 · Cited by 98
Ha, J.-H., Kim, J.-E., & Kim, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00394 · Cited by 97
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95 · cited 3×
“These moieties are symmetrical with two identical fragment antigen-specific binding (Fab) regions and one fragment crys allizabl (Fc) region [3].”
BackgroundInfluentialSelf-citationShatz-Binder, W., Chung, S., Li, B., Marshall, B., Tejada, M. L., Phung, W., Sandoval, W. N., Kelley, R. F., & Scheer, J. M. (2013) · mAbs · doi:10.4161/mabs.26307 · Cited by 94
Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
Xu, Y.-R., Lee, J., Tran, C., Heibeck, T. H., Wang, W. D., Yang, J.-H., Stafford, R., Steiner, A. R., Sato, A., Hallam, T., et al. (2014) · mAbs · doi:10.4161/19420862.2015.989013 · Cited by 91
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Self-citationReusch, U., Harrington, K. H., Gudgeon, C. J., Fucek, I., Ellwanger, K., Weichel, M., Knackmuss, S. H. J., Zhukovsky, E. A., Fox, J. A., Kunkel, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0350 · Cited by 90
Mack, M., Gruber, R., Schmidt, S., Riethmüller, G., & Kufer, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3965 · Cited by 86
Properties of a single-chain antibody containing different linker peptides
Alfthan, K., Takkinen, K., Sizmann, D., Söderlund, H., & Teeri, T. T. (1995) · Protein Engineering Design and Selection · doi:10.1093/protein/8.7.725 · Cited by 82
de Marco, A., & Marco, V. D. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2003.10.025 · Cited by 81
Rapid protein production using CHO stable transfection pools
Ye, J., Alvin, K., Latif, H., Hsu, A. H.-M., Parikh, V., Whitmer, T., Tellers, M., Edmonds, M. C. D. L. C., Ly, J., Salmon, P. M., et al. (2010) · Biotechnology Progress · doi:10.1002/btpr.469 · Cited by 80
Rader, C. M. (2011) · Blood · doi:10.1182/blood-2011-02-337691 · Cited by 79
Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments
Gil, D., & Schrum, A. G. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.44a011 · Cited by 78
Consensus-Based Engineering of Protein Stability: From Intrabodies to Thermostable Enzymes
Steipe, B. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)88016-9 · Cited by 76
Moore, G. L., Bernett, M. J., Rashid, R., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Nisthal, A., Diaz, J. E., Chu, S. Y., et al. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.006 · Cited by 76
Dillon, M., Yin, Y., Zhou, J., McCarty, L., Ellerman, D., Slaga, D., Junttila, T. T., Han, G., Sandoval, W., Ovacik, M. A., et al. (2017) · mAbs · doi:10.1080/19420862.2016.1267089 · Cited by 75
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
Yang, F., Wen, W., & Qin, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010048 · Cited by 75
Glycosylation of IgG-Fc: a molecular perspective
Kiyoshi, M., Tsumoto, K., Ishii‐Watabe, A., & Caaveiro, J. M. M. (2017) · International Immunology · doi:10.1093/intimm/dxx038 · Cited by 74
Thomas, M., Kienast, Y., Scheuer, W., Bähner, M., Kaluza, K., Gassner, C., Herting, F., Brinkmann, U., Seeber, S., Kavlie, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054923 · Cited by 73
Stech, M., Hust, M., Schulze, C., Dübel, S., & Kubick, S. (2014) · Engineering in Life Sciences · doi:10.1002/elsc.201400036 · Cited by 71
Stadler, C., Bähr-Mahmud, H., Plum, L. M., Schmoldt, K., Kölsch, A. C., Türeci, Ö., & Şahin, U. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1091555 · Cited by 66
Borras, L., Gunde, T., Tietz, J., Bauer, U., Hulmann, V., Grimshaw, J. P. A., & Urech, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072876 · Cited by 64
Wang, R., Xiang, S., Feng, Y., Srinivas, S., Zhang, Y., Lin, M., & Wang, S. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00072 · Cited by 62
A novel method for determining antibody-dependent cellular phagocytosis
Kamen, L. A., Myneni, S., Langsdorf, C., Kho, E., Ordonia, B., Thakurta, T. G., Zheng, K., Song, A., & Chung, S. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.03.001 · Cited by 62
Engineering IgG-Like Bispecific Antibodies—An Overview
Krah, S., Kolmar, H., Becker, S., & Zielonka, S. (2018) · Antibodies · doi:10.3390/antib7030028 · Cited by 61
Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers
Dall’Acqua, W. F., Simon, A. L., Mulkerrin, M. G., & Carter, P. M. (1998) · Biochemistry · doi:10.1021/bi980270i · Cited by 60
Selection of Linkers for a Catalytic Single-chain Antibody Using Phage Display Technology
Tang, Y., Jiang, N., Parakh, C., & Hilvert, D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.26.15682 · Cited by 59
High‐throughput screening and selection of mammalian cells for enhanced protein production
Priola, J. J., Calzadilla, N., Baumann, M., Borth, N., Tate, C. G., & Betenbaugh, M. J. (2016) · Biotechnology Journal · doi:10.1002/biot.201500579 · Cited by 57
Self-citationNakanishi, T., Tsumoto, K., Yokota, A., Kondo, H., & Kumagai, I. (2008) · Protein Science · doi:10.1110/ps.073156708 · Cited by 56
Brockmann, E., Cooper, M., Strömsten, N., Vehniäinen, M., & Saviranta, P. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.11.008 · Cited by 55
Muda, M., Gross, A. W., Dawson, J., He, C., Kurosawa, E., Schweickhardt, R. L., Dugas, M., Soloviev, M., Bernhardt, A., Fischer, D., et al. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq123 · Cited by 55
Shiraiwa, H., Narita, A., Kamata‐Sakurai, M., Ishiguro, T., Sano, Y., Hironiwa, N., Tsushima, T., Segawa, H., Tsunenari, T., Ikeda, Y., et al. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.005 · Cited by 55
Harnessing the cell death pathway for targeted cancer treatment.
Speirs, C. K., Hwang, M., Kim, S., Li, W., Chang, S., Varki, V., Mitchell, L., Schleicher, S. M., & Lu, B. (2011) · American Journal of Cancer Research · Cited by 53
Kuo, S.-R., Wong, L., & Liu, J.-S. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs040 · Cited by 52
Crystal Structure of the Anti-His Tag Antibody 3D5 Single-chain Fragment Complexed to its Antigen
Kaufmann, M., Lindner, P. J., Honegger, A., Blank, K. G., Tschopp, M., Capitani, G., Plückthun, A., & Grütter, M. G. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00038-4 · Cited by 48
Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging
Power, B. E., & Hudson, P. J. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00201-5 · Cited by 47
Zhao, J., Yang, L., Gu, Z., Chen, H.-Q., Tian, F., Chen, Y. Q., Zhang, H., & Chen, W. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms12010001 · Cited by 46
Self-citationMonsellier, É., & Bedouelle, H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.044 · Cited by 46
Sonoda, H., Kumada, Y., Katsuda, T., & Yamaji, H. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2010.12.015 · Cited by 45
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
Blarcom, T. J. V., Lindquist, K. C., Melton, Z., Cheung‐Lee, W. L., Wagstrom, C., McDonough, D., Oseguera, C. A. V., Ding, S., Rossi, A., Potluri, S., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1406570 · Cited by 42
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new?
Ponz‐Sarvisé, M., Rodríguez, J., Viudez, A., Chopitea, A., Calvo, A., García-Foncillas, J., & Gil-Bazo, I. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5877 · Cited by 41
Makvandi‐Nejad, S., McLean, M. D., Hirama, T., Almquist, K. C., MacKenzie, C. R., & Hall, J. C. (2005) · Transgenic Research · doi:10.1007/s11248-005-7461-0 · Cited by 39
Zhang, H., Li, C., Lei, M., Lundin, V., Lee, H., Niñonuevo, M. R., Lin, K., Han, G., Sandoval, W. N., Lei, D., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03830 · Cited by 37
Sonoda, H., Kumada, Y., Katsuda, T., & Yamaji, H. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2009.11.003 · Cited by 36
Chemically Programmed Bispecific Antibodies in Diabody Format
Walseng, E., Nelson, C. G., Qi, J., Nanna, A. R., Roush, W. R., Goswami, R. K., Sinha, S. C., Burke, T. R., & Rader, C. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.745588 · Cited by 35
Compte, M., Álvarez‐Cienfuegos, A., Nuñez‐Prado, N., Sainz-Pastor, N., Blanco‐Toribio, A., Pescador, N., Sanz, L., & Álvarez‐Vallina, L. (2014) · OncoImmunology · doi:10.4161/onci.28810 · Cited by 34
Regula, J. T., Imhof-Jung, S., Mølhøj, M., Benz, J., Ehler, A., Bujotzek, A., Schäfer, W. M., & Klein, C. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy021 · Cited by 34
Ekerljung, L., Wållberg, H., Sohrabian, A., Andersson, K., Friedman, M., Frejd, F. Y., Ståhl, S., & Gedda, L. (2012) · Bioconjugate Chemistry · doi:10.1021/bc3000645 · Cited by 32
Production of Stabilized scFv Antibody Fragments in the E. coli Bacterial Cytoplasm
Vaks, L., & Benhar, I. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_10 · Cited by 29
Expression of Single-Chain Fv Fragments in E. coli Cytoplasm
Guglielmi, L., & Martineau, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-302-2_17 · Cited by 29
An efficient route to bispecific antibody production using single-reactor mammalian co-culture
Shatz-Binder, W., Ng, D., Dutina, G., Wong, A. W., Dunshee, D. R., Sonoda, J., Shen, A. Y., & Scheer, J. M. (2016) · mAbs · doi:10.1080/19420862.2016.1234569 · Cited by 28
Optimizing assembly and production of native bispecific antibodies by codon de-optimization
Magistrelli, G., Poitevin, Y., Schlosser, F., Pontini, G., Malinge, P., Josserand, S., Corbier, M., & Fischer, N. (2017) · mAbs · doi:10.1080/19420862.2016.1267088 · Cited by 28
High-Level Periplasmic Expression and Purificationof scFvs
Kipriyanov, S. M. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-302-2_16 · Cited by 27
Vendel, M. C., Favis, M., Snyder, W. B., Huang, F., Capili, A. D., Dong, J., Glaser, S., Miller, B., & Demarest, S. J. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.12.018 · Cited by 27
Bispecific antibodies for treatment of cancer in experimental animal models and man
Kroesen, B. J., Helfrich, W., Molema, G., & de Leij, L. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00096-3 · Cited by 27
Rajendra, Y., Peery, R. B., Hougland, M. D., Barnard, G. C., Wu, X., Fitchett, J. R., Bacica, M., & Demarest, S. J. (2016) · Biotechnology Progress · doi:10.1002/btpr.2414 · Cited by 25
Screening of a ScFv Antibody With High Affinity for Application in Human IFN-γ Immunoassay
Yang, H., Zhong, Y., Wang, J., Zhang, Q., Li, X., Ling, S., Wang, S., & Wang, R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00261 · Cited by 25
Long, N. E., Sullivan, B. J., Ding, H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002538 · Cited by 25
Dimasi, N., Fleming, R. L., Wu, H., & Gao, C. (2018) · Methods · doi:10.1016/j.ymeth.2018.08.004 · Cited by 23
Harnessing the cell death pathway for targeted cancer treatment
Speirs, C. K., Hwang, M., Kim, S., Li, W., Chang, S., Varki, V., Mitchell, L., Schleicher, S., & Lu, B. (2010) · Europe PMC (PubMed Central) · Cited by 22
Pokkuluri, P. R., Gu, M., Cai, X., Raffen, R., Stevens, F. J., & Schiffer, M. (2002) · Protein Science · doi:10.1110/ps.4920102 · Cited by 21
Construction and periplasmic expression of the Anti-EGFRvIII ScFv antibody gene in Escherichia coli
DEWI, K. S. (2016) · Scientia Pharmaceutica · doi:10.3797/scipharm.isp.2015.06 · Cited by 18
Lin, L., Li, L., Zhou, C., Li, J., Liu, J., Shu, R., Dong, B., Li, Q., & Wang, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.8698 · Cited by 18
Gomez, N. V., Wieczorek, A., Lu, F., Bruno, R., Diaz, L., Agrawal, N. J., & Daris, K. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26803 · Cited by 18
Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab
Zhao, L., Xie, F., Tong, X., Li, H., Chen, Y., Qian, W., Duan, S., Zheng, J., Zhao, Z., Li, B., et al. (2014) · mAbs · doi:10.4161/mabs.28613 · Cited by 17
Self-citationHao, C.-H., Han, Q., Shan, Z., Hu, J., Zhang, N., & Zhang, X. (2015) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-015-0010-5 · Cited by 8
Chi, W., Kim, H., Hee-Jung, Y., Kim, Y. P., & Hong, S. (2016) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-015-0817-2 · Cited by 5
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Multispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Metadata
- Authors
- Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2019-08-02
- Volume
- 8
- Issue
- 3
- Pages
- 43
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2966732164
- Cited by
- 279
- References
- 163
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.